MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$27.66

Market cap

$2.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.8

Enterprise value

$2.55B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
Myriad Genetics's revenue has increased by 11% YoY and by 2.8% QoQ
The gross profit is up by 11% year-on-year and by 3% since the previous quarter
The company's net income has shrunk by 60% YoY but it rose by 11% QoQ
The EPS has plunged by 56% YoY but it has grown by 12% from the previous quarter
The company's equity fell by 9% YoY and by 3% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/
Peers: EXAS BMRN BIO ABT

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
90.51M
Market cap
$2.5B
Enterprise value
$2.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.27
Price to sales (P/S)
3.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.3
Earnings
Revenue
$774.2M
EBIT
-$232.6M
EBITDA
-$163.7M
Free cash flow
-$154.7M
Per share
EPS
-$2.8
Free cash flow per share
-$1.72
Book value per share
$8.46
Revenue per share
$8.61
TBVPS
$5.37
Balance sheet
Total assets
$1.11B
Total liabilities
$350.5M
Debt
$146.8M
Equity
$760M
Working capital
$144.2M
Liquidity
Debt to equity
0.19
Current ratio
1.99
Quick ratio
1.52
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-21.1%
Gross margin
68.8%
Net margin
-30.3%
Operating margin
-30.1%
Efficiency
Return on assets
-20.4%
Return on equity
-31.7%
Return on invested capital
-58%
Return on capital employed
-24.1%
Return on sales
-30%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-0.68%
1 week
6.51%
1 month
12.35%
1 year
25.22%
YTD
44.51%
QTD
13.08%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$774.2M
Gross profit
$532.6M
Operating income
-$233.1M
Net income
-$234.6M
Gross margin
68.8%
Net margin
-30.3%
The company's net income has shrunk by 60% YoY but it rose by 11% QoQ
The net margin has contracted by 44% YoY but it has grown by 13% from the previous quarter
The operating income fell by 39% YoY but it rose by 9% QoQ
The company's operating margin fell by 25% YoY but it rose by 12% QoQ

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
3.27
P/S
3.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.3
The EPS has plunged by 56% YoY but it has grown by 12% from the previous quarter
MYGN's price to book (P/B) is 73% higher than its 5-year quarterly average of 1.9 and 43% higher than its last 4 quarters average of 2.3
The company's equity fell by 9% YoY and by 3% QoQ
The P/S is 40% higher than the last 4 quarters average of 2.3 and 29% higher than the 5-year quarterly average of 2.5
Myriad Genetics's revenue has increased by 11% YoY and by 2.8% QoQ

Efficiency

How efficient is Myriad Genetics business performance
MYGN's return on equity has dropped by 94% year-on-year but it is up by 9% since the previous quarter
The return on invested capital has dropped by 71% year-on-year but it has grown by 5% since the previous quarter
Myriad Genetics's return on assets has shrunk by 67% YoY but it has increased by 10% QoQ
The ROS has contracted by 27% YoY but it has grown by 13% from the previous quarter

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
The quick ratio has increased by 10% year-on-year but it has declined by 7% since the previous quarter
Myriad Genetics's current ratio has increased by 9% YoY
The debt is 81% less than the equity
The debt has contracted by 9% YoY and by 3.5% from the previous quarter
The company's equity fell by 9% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.